WO2006085973A3 - Antisense antibacterial method and compound - Google Patents

Antisense antibacterial method and compound Download PDF

Info

Publication number
WO2006085973A3
WO2006085973A3 PCT/US2005/023553 US2005023553W WO2006085973A3 WO 2006085973 A3 WO2006085973 A3 WO 2006085973A3 US 2005023553 W US2005023553 W US 2005023553W WO 2006085973 A3 WO2006085973 A3 WO 2006085973A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
bases
bacterial
antisense
mrna
Prior art date
Application number
PCT/US2005/023553
Other languages
French (fr)
Other versions
WO2006085973A2 (en
Inventor
Bruce L Geller
Jesse D Deere
Patrick L Iversen
Original Assignee
Avi Biopharma Inc
Bruce L Geller
Jesse D Deere
Patrick L Iversen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avi Biopharma Inc, Bruce L Geller, Jesse D Deere, Patrick L Iversen filed Critical Avi Biopharma Inc
Priority to AU2005327188A priority Critical patent/AU2005327188C9/en
Priority to EP05857499A priority patent/EP1766012B1/en
Priority to CA 2571593 priority patent/CA2571593C/en
Priority to PL05857499T priority patent/PL1766012T3/en
Priority to AT05857499T priority patent/ATE510914T1/en
Priority to SI200531354T priority patent/SI1766012T1/en
Priority to DK05857499.7T priority patent/DK1766012T3/en
Publication of WO2006085973A2 publication Critical patent/WO2006085973A2/en
Publication of WO2006085973A3 publication Critical patent/WO2006085973A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65613—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system (X = CH2, O, S, NH) optionally with an additional double bond and/or substituents, e.g. cephalosporins and analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring

Abstract

A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication. The compound binds to a target mRNA with a Tm of between 50 °C to 60 °C. The relatively short antisense compound are substantially more active than conventional antisense compounds having a targeting base sequence of 15 or more bases.
PCT/US2005/023553 2004-07-02 2005-07-01 Antisense antibacterial method and compound WO2006085973A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2005327188A AU2005327188C9 (en) 2004-07-02 2005-07-01 Antisense antibacterial method and compound
EP05857499A EP1766012B1 (en) 2004-07-02 2005-07-01 Antisense antibacterial method and compound
CA 2571593 CA2571593C (en) 2004-07-02 2005-07-01 Antisense antibacterial method and compound
PL05857499T PL1766012T3 (en) 2004-07-02 2005-07-01 Antisense antibacterial method and compound
AT05857499T ATE510914T1 (en) 2004-07-02 2005-07-01 ANTISENSE ANTIBACTERIAL PROCESSES AND COMPOUNDS
SI200531354T SI1766012T1 (en) 2004-07-02 2005-07-01 Antisense antibacterial method and compound
DK05857499.7T DK1766012T3 (en) 2004-07-02 2005-07-01 Antisense antibacterial method and compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58511204P 2004-07-02 2004-07-02
US60/585,112 2004-07-02

Publications (2)

Publication Number Publication Date
WO2006085973A2 WO2006085973A2 (en) 2006-08-17
WO2006085973A3 true WO2006085973A3 (en) 2007-04-12

Family

ID=36686070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/023553 WO2006085973A2 (en) 2004-07-02 2005-07-01 Antisense antibacterial method and compound

Country Status (12)

Country Link
US (4) US8314072B2 (en)
EP (2) EP1766012B1 (en)
AT (1) ATE510914T1 (en)
AU (1) AU2005327188C9 (en)
CA (2) CA2875436A1 (en)
CY (1) CY1111765T1 (en)
DK (1) DK1766012T3 (en)
ES (1) ES2367289T3 (en)
PL (1) PL1766012T3 (en)
PT (1) PT1766012E (en)
SI (1) SI1766012T1 (en)
WO (1) WO2006085973A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171044A1 (en) * 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
PT1766012E (en) * 2004-07-02 2011-09-05 Avi Biopharma Inc Antisense antibacterial method and compound
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
EP1915161B1 (en) * 2005-07-13 2017-04-26 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
EP2023939B1 (en) 2006-05-05 2012-06-27 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of pcsk9
PT2735568T (en) * 2006-05-10 2017-11-14 Avi Biopharma Inc Oligonucleotide analogs having cationic intersubunit linkages
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EP2102340A2 (en) * 2006-11-27 2009-09-23 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US9050373B2 (en) 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
KR101981705B1 (en) 2010-05-28 2019-05-24 사렙타 쎄러퓨틱스, 인코퍼레이티드 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
JP6023705B2 (en) * 2010-06-23 2016-11-09 カッパーアールエヌエー，インコーポレイテッド Treatment of SCNA-related diseases by inhibition of natural antisense transcripts on sodium channels, voltage-gated, alpha subunit (SCNA)
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
US20120122769A1 (en) * 2010-11-12 2012-05-17 Avi Biopharma, Inc. Antisense antibacterial compounds and methods
CN103501793A (en) 2011-02-08 2014-01-08 夏洛特-梅克伦堡医院(商业用名:卡罗来纳保健系统) Antisense oligonucleotides
CN104039739A (en) 2011-11-18 2014-09-10 萨勒普塔医疗公司 Functionally-modified oligonucleotides and subunits thereof
CN104411831B (en) 2012-03-20 2020-08-11 萨勒普塔医疗公司 Boronic acid conjugates of oligonucleotide analogs
EP3620178A3 (en) 2014-05-16 2020-07-22 Oregon State University Antisense antibacterial compounds and methods
CA2948568A1 (en) 2014-05-19 2015-11-26 David Greenberg Antisense antibacterial compounds and methods
US10266823B2 (en) * 2014-07-01 2019-04-23 The University Of North Carolina At Chapel Hill Small molecules that enhance the activity of oligonucleotides
WO2016108930A2 (en) * 2014-12-31 2016-07-07 Geller Bruce L Antisense antibacterial compounds and methods
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
CA3010084A1 (en) 2015-12-23 2017-06-29 Oregon State University Antisense antibacterial compounds and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049775A2 (en) * 2000-01-04 2001-07-12 Avi Biopharma, Inc. Antisense antibacterial cell division composition and method
WO2002079467A2 (en) * 2001-03-29 2002-10-10 Københavns Universitet Antibiotic-free bacterial strain selection with antisense molecules

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166315A (en) * 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
DE3650349T2 (en) 1985-03-15 1995-12-14 Antivirals Inc IMMUNOTEST FOR POLYNUCLEOTID AND METHOD.
US5185444A (en) * 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5217866A (en) * 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5749847A (en) * 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
ATE220407T1 (en) 1989-12-20 2002-07-15 Antivirals Inc UNCHARGED MORPHOLINE BASED POLYMERS WITH CHIRAL PHOSPHORUS CONTAINING BRIDGES BETWEEN SUBUNITS
US5852188A (en) * 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
AU652577B2 (en) 1990-08-14 1994-09-01 Isis Pharmaceuticals, Inc. Inhibition of influenza virus type A, Ann Arbor strain H2N2 by antisense oligonucleotides
JPH07501204A (en) 1991-06-28 1995-02-09 マサチューセッツ インスティテュート オブ テクノロジー Topical oligonucleotide therapy
US6030954A (en) * 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US5821052A (en) 1992-04-16 1998-10-13 University Of Medicine And Dentistry Of New Jersey Control of the synthesis of proteins by anitisense RNA-tRNA complex
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6060456A (en) * 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
US5479847A (en) * 1994-11-07 1996-01-02 Marlen Research Corporation Dual-piston pump apparatus
GB9505438D0 (en) 1995-03-17 1995-05-03 Sod Conseils Rech Applic Antisense oligonucleotides
GB9510718D0 (en) * 1995-05-26 1995-07-19 Sod Conseils Rech Applic Antisense oligonucleotides
EP0966303A2 (en) 1996-05-01 1999-12-29 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
AU3811897A (en) 1996-07-24 1998-02-10 Oglios Therapeutics, Inc. Antisense oligonucleotides as antibacterial agents
AU742521B2 (en) 1997-01-24 2002-01-03 Avi Biopharma, Inc. Method and conjugate for treating H. pylori infection
ES2210761T3 (en) * 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University COMPOSITION AND PROCEDURE TO IMPROVE TRANSPORTATION THROUGH BIOLOGICAL MEMBERS.
US6204019B1 (en) 1997-06-04 2001-03-20 Smithkline Beecham Corporation Sec A2 from Streptococcus pneumoniae
US6610539B1 (en) 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
EP0894857A3 (en) 1997-08-01 2001-09-26 Smithkline Beecham Corporation SecA gene from Streptococcus pneumoniae
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6228579B1 (en) * 1997-11-14 2001-05-08 San Diego State University Foundation Method for identifying microbial proliferation genes
US6548651B1 (en) * 1998-11-11 2003-04-15 Pantheco A/S Modified peptide nucleic acid (PNA) molecules
US7094765B1 (en) * 1999-01-29 2006-08-22 Avi Biopharma, Inc. Antisense restenosis composition and method
WO2000045167A2 (en) * 1999-01-29 2000-08-03 Avi Biopharma, Inc. Non-invasive method for detecting target rna
US6521438B1 (en) * 1999-11-05 2003-02-18 North Carolina State University Chemoreceptors in plant parasitic nematodes
US20030095953A1 (en) * 1999-11-12 2003-05-22 Myles C. Cabot Methods of reversing drug resistance in cancer cells
EP1238071B1 (en) * 1999-11-29 2008-04-23 Avi Biopharma, Inc. Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s rrnas and their uses
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US20040072743A1 (en) * 2000-04-06 2004-04-15 Christensen Jeppe Viggo Pharmaceutical composition of modified pna molecules
WO2001083740A2 (en) * 2000-05-04 2001-11-08 Avi Biopharma, Inc. Splice-region antisense composition and method
AU2001271873A1 (en) * 2000-07-06 2002-01-21 Avi Biopharma, Inc. Transforming growth factor beta (TGF-beta) blocking agent-treated stem cell composition and method
AU2002214127B2 (en) * 2000-10-27 2007-06-07 J. Craig Venter Institute, Inc. Nucleic acids and proteins from streptococcus groups A and B
WO2002094250A2 (en) * 2001-05-18 2002-11-28 Cureon A/S Therapeutic uses of lna-modified oligonucleotides in infectious diseases
JP2005507660A (en) * 2001-10-16 2005-03-24 アビ バイオファーマ， インコーポレイテッド Antisense antiviral agents and methods for the treatment of ssRNA virus infections
US20030224353A1 (en) * 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
WO2004041854A2 (en) * 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Essential novel bacterial polypeptides
US7468418B2 (en) 2003-04-29 2008-12-23 Avi Biopharma., Inc. Compositions for enhancing transport of molecules into cells
EP1627226A1 (en) * 2003-05-23 2006-02-22 Ecole Polytechnique Federale De Lausanne Methods for protein labeling based on acyl carrier protein
AU2004276226B2 (en) 2003-08-05 2009-07-30 Avi Biopharma, Inc. Oligonucleotide analog and method for treating flavivirus infections
US7402574B2 (en) 2004-03-12 2008-07-22 Avi Biopharma, Inc. Antisense composition and method for treating cancer
PT1766012E (en) 2004-07-02 2011-09-05 Avi Biopharma Inc Antisense antibacterial method and compound
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US8067571B2 (en) * 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
EP1915161B1 (en) 2005-07-13 2017-04-26 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
PT2735568T (en) 2006-05-10 2017-11-14 Avi Biopharma Inc Oligonucleotide analogs having cationic intersubunit linkages
WO2013012752A2 (en) 2011-07-15 2013-01-24 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049775A2 (en) * 2000-01-04 2001-07-12 Avi Biopharma, Inc. Antisense antibacterial cell division composition and method
WO2002079467A2 (en) * 2001-03-29 2002-10-10 Københavns Universitet Antibiotic-free bacterial strain selection with antisense molecules

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DEERE JESSE ET AL: "Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. JAN 2005, vol. 49, no. 1, January 2005 (2005-01-01), pages 249 - 255, XP002402833, ISSN: 0066-4804 *
DRYSELIUS RIKARD ET AL: "The translation start codon region is sensitive to antisense PNA inhibition in Escherichia coli.", OLIGONUCLEOTIDES. 2003, vol. 13, no. 6, 2003, pages 427 - 433, XP002402830, ISSN: 1545-4576 *
GELLER B L ET AL: "Inhibition of gene expression in Escherichia coli by antisense phosphorodiamidate morpholino oligomers.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. OCT 2003, vol. 47, no. 10, October 2003 (2003-10-01), pages 3233 - 3239, XP002402831, ISSN: 0066-4804 *
GOOD LIAM ET AL: "Bactericidal antisense effects of peptide-PNA conjugates", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 19, no. 4, April 2001 (2001-04-01), pages 360 - 364, XP002187946, ISSN: 1087-0156 *
NIELSEN P E: "PEPTIDE NUCLEIC ACIDS AS ANTIBACTERIAL AGENTS VIA THE ANTISENSE PRINCIPLE", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 10, no. 2, February 2001 (2001-02-01), pages 331 - 341, XP001052987, ISSN: 1354-3784 *
WANG BING ET AL: "Assessment of the utilization of the antisense RNA strategy to identify essential genes in heterologous bacteria.", FEMS MICROBIOLOGY LETTERS, vol. 220, no. 2, 28 March 2003 (2003-03-28), pages 171 - 176, XP002402832, ISSN: 0378-1097 *

Also Published As

Publication number Publication date
US7625873B2 (en) 2009-12-01
US20130289091A1 (en) 2013-10-31
DK1766012T3 (en) 2011-09-19
AU2005327188C8 (en) 2011-09-22
US20100137408A1 (en) 2010-06-03
EP2351839A2 (en) 2011-08-03
CA2571593A1 (en) 2006-08-17
AU2005327188C1 (en) 2011-07-07
US9534220B2 (en) 2017-01-03
ES2367289T3 (en) 2011-11-02
US20070021362A1 (en) 2007-01-25
AU2005327188C9 (en) 2011-09-22
CA2571593C (en) 2015-04-21
ATE510914T1 (en) 2011-06-15
US8314072B2 (en) 2012-11-20
CA2875436A1 (en) 2006-08-17
EP1766012A2 (en) 2007-03-28
PT1766012E (en) 2011-09-05
SI1766012T1 (en) 2011-10-28
EP1766012B1 (en) 2011-05-25
AU2005327188A1 (en) 2006-08-17
US20070049542A1 (en) 2007-03-01
WO2006085973A2 (en) 2006-08-17
CY1111765T1 (en) 2015-10-07
EP2351839A3 (en) 2011-10-05
AU2005327188B2 (en) 2011-03-17
PL1766012T3 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
WO2006085973A3 (en) Antisense antibacterial method and compound
WO2007009094A3 (en) Antisense antibacterial method and compound
WO2007051045A3 (en) Compositions and methods for inhibiting expression of huntingtin gene
WO2007056326A3 (en) Compositions and methods for inhibiting expression of nav1.8 gene
WO2002026967A3 (en) Targeted gene correction by single-stranded oligodeoxynucleotides
WO2007115168A8 (en) Compositions and methods for inhibiting expression of eg5 gene
WO2007134161A3 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
WO2004065580A3 (en) Mesecnhymal stem cells as a vehicle for ion channel transfer in syncytial structures
WO2006040357A3 (en) Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2006119266A3 (en) Human micrornas and methods for inhibiting same
WO2005047477A3 (en) Interspersed repetitive element rnas as substrates, inhibitors and delivery vehicles for rnai
WO2008036933A3 (en) Compositions and methods for inhibiting expression of the hamp gene
WO2007005645A3 (en) Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
WO2008008719A3 (en) Compositions and methods for inhibiting expression of the myc gene
WO2006032041A3 (en) Compositions and methods for inhibiting expression of anti-apoptotic genes
WO2009104001A3 (en) Oligopeptidic compounds and uses thereof
WO2006056487A3 (en) Peptides useful as dual caspase-2/-6 inhibitors and their biological applications
WO2008092081A3 (en) Targeted delivery of sirna
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
WO2010013815A1 (en) Composition for inhibiting expression of target gene
WO2009047992A1 (en) Udp-glucuronyl transferase and polynucleotide encoding the same
WO2007137220A3 (en) Compositions and methods for inhibiting expression of ikk-b gene
WO2007056331A3 (en) Compositions and methods for inhibiting expression of factor v leiden mutant gene
WO2008001219A3 (en) Cancer therapy using bcl-xl-specific sina
EP1248633A4 (en) Antisense modulation of glycogen synthase kinase 3 beta expression

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005327188

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2571593

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

ENP Entry into the national phase

Ref document number: 2005327188

Country of ref document: AU

Date of ref document: 20050701

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005327188

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005857499

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005857499

Country of ref document: EP